Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy

Hematology/Oncology Clinics of North America

Volumn 10, Issue 4, 1996, Pages 825-840

  Lifton, R ^a   Bennett, J M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER; CANCER SURVIVAL; INFECTION; NEUTROPENIA; PRIORITY JOURNAL; REVIEW;

EID: 0029899636     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70371-3     Document Type: Article

References (49)

1. C. Anasetti R. Etzioni Unrelated and HLA-partially matched related donor transplants [abstract] Cell Biochem 18B 1994 48
2. J.H. Antin B.R. Smith Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome Blood 72 1988 705 713
3. E. Archimbaud P. Fenaux Granulocyte-macrophage colony-stimulating factor in association with time-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia Leukemia 7 1993 372
4. S. Asamo T. Masaoka Beneficial effect of recombinant human glycosylated granulocyte colony-stimulating factor in marrow-transplanted patients: Results of multicenter phase II-III studies Transplant Proc 23 1991 1701 1703
5. P. Bettelheim P. Valent Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia Blood 77 1991 700
6. T. Buchner W. Hiddemann Multiple course chemotherapy with or without GM-CSF priming and long-term administration for newly diagnosed AML [abstract] Proc Am Soc Clin Oncol 12 1993 301
7. T. Bfichner W. Hiddemann Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse Blood 78 1991 1190
8. J. Crawford H. Ozer Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-met HuG-CSF) N Engl J Med 325 1991 164 170
9. T. De Witte G. Vreugdenhil Prolonged administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) after T-cell-depleted allogeneic bone marrow transplantation Transplant Proc 25 1993 57 60
10. H. Dombret C. Chastang A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia N Engl J Med 332 1995 1678 1683
11. E.H. Estey Use of colony-stimulating factors in the treatment of acute myeloid leukemia Blood 83 1994 2015 2019
12. E.H. Estey D. Dixon Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor Blood 75 1990 1766
13. E.H. Estey R. Kurzrock Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes Br J Haematol 77 1991 291 295
14. E. Estey P.F. Thall Treatment of newly diagnosed acute myelogenous leukemiawith granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF Blood 79 1992 2246
15. Estey E, Thall P, et al: Use of G-CSF before, during, and after fiudarabine + ara-C induction therapy of newly diagnosed AML or MDS: Comparison with fiudarabine + ara-C without G-CSF. J Clin Oncol, in press
16. A. Ganser B. Volkers Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes—a phase I/II trial Blood 73 1989 31 37
17. C. Gisselbrecht H.G. Prentice Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation Lancet 343 1994 696 700
18. G. Heil L. Chadid GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML) Leukemia 9 1995 3 9
19. F. Herrmann A. Lindemann Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts Leukemia 3 1989 335 338
20. A. Hiraoaka T. Masaoka Five years follow-up of a randomized placebo-controlled study with filgrastim (recombinant human granulocyte colony-stimulating factor) in patients receiving allogeneic bone-marrow transplantation [abstract] Blood 86 suppl 1 1995 222a
21. H. Kerkhofs J. Hermans Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases Br J Haematol 65 1987 73 81
22. Y. Kobayashi T. Okabe Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A preliminary report Am J Med 86 1989 178 182
23. H.M. Lazarus J.M. Rowe Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation Blood Reviews 8 1994 169 178
24. T. Maekawa D. Metcalf Clonal suppression of HL60 and U937 cells by recombinant leukemia inhibitory factor in combination with GM-CSF or G-CSF Leukemia 3 1989 270 276
25. T. Masaoka F. Takaku Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation Exp Hematol 17 1989 1047 1050
26. J. Mehta R. Powles GM-CSF after allogeneic bone marrow transplantation for hematologic malignancies: 5-year follow-up [abstract] Blood 86 suppl 1 1995 385a
27. D. Metcalf N.A. Nicola Biological actions of the colony-stimulating factors in vitro The Hemopoietic Colony-Stimulating Factors, From Biology to Clinical Applications 1995 Cambridge University Press Australia
28. D. Metcalf N.A. Nicola The colony-stimulating factors and myeloid leukemia. I~ The Hemopoietic Colony-Stimulating Factors, From Biology to Clinical Applications 1995 Cambridge University Press Australia
29. D. Metcalf J.E.J. Rasko Leukemic transformation of immortalized FDC-P1 cells engrafted in GM-CSF transgenic mice Leukemia 7 1993 878 886
30. L.L. Miller H. Ozer American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines J Clin Oncol 12 1994 2471 2508
31. R.S. Negrin D.H. Haeuber Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor Blood 76 1990 36 43
32. R.S. Negrin D.H. Haeuber Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A phase I/II trial Ann Intern Med 110 1989 9476 9484
33. J. Nemunaitis C. Anasetti Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors Blood 79 1992 2572 2577
34. J. Nemunaitis S.N. Rabinowe Recombinant granulocyte-macrophage colony-stimulatingfactor after autologous bone marrow transplantation for lymphoid cancer N Engl J Med 324 1991 1773 1778
35. J. Nemunaitis C. Rosenreid Phase III double-blind trial of rhGM-CSF (sargramostim) following allogeneic bone marrow transplant (BMT) [abstract] Blood 82 suppl 1 1993 286a
36. J. Nemunaitis J.W. Singer The use of recombinant human granulocyte-macrophage colony-stimulating factor for graff failure in patients after bone marrow transplantation Blood 76 1990 245 253
37. R. Ohno T. Naoe A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia Blood 83 1994 2086
38. R. Ohno M. Tomonaga Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia N Engl J Med 323 1990 871
39. R. Powles C. Smith Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: Double-blind, placebo-controlled trial Lancet 336 1990 1417 1420
40. C. Rose E. Wattel Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases Leukemia 8 1994 1458 1462
41. J.M. Rowe J. Andersen Phase III randomized placebo-controlled study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (55-70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG) [abstract] Blood 82 suppl 1 1993 329a
42. J.M. Rowe J.W. Andersen A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490) Blood 86 1995 457 462
43. J.R. Schriber N.J. Chao Granulocyte colony stimulating factor (G-CSF) following allogeneic bone marrow transplantation [abstract] Blood 82 suppl 1 1993 286a
44. J.A. Schuster R. Thompson Randomized phase II study of recombinant granulocyte macrophage-colony stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS) [abstract] Blood 86 suppl 1 1995 338a
45. R.S. Stein Clinical use of growth factors in the myelodysplastic syndromes Am J Med $ci 307 1994 360 367
46. R.M. Stone D.T. Berg Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia N Engl J Med 332 1995 1671 1678
47. J.A. Thompson D.J. Lee Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics, and hematological effects J Clin Oncol 7 1989 629 637
48. S. Vadhan-Raj M. Keating Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes N Engl J Med 317 1987 1545 1552
49. R. Willemze H. van der Lely A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia Ann Hematol 64 1992 173 180